Long-acting HIV prevention injection trials resumed

The HIV Prevention Trials Network (HPTN) 084, is a study being done to evaluate the safety and efficacy of the injectable agent, cabotegravir (CAB LA) compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), for pre-exposure prophylaxis (PrEP) in HIV-uninfected women.

When addressing different stakeholder at the HPTN meeting at the institution at Princess Marina Referral Hospital this week, Shava said they had to put the study on hold last year after there were misunderstanding over the DTG drug used to treat HIV infection.